Biofrontera Inc.
BFRIAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Benchmark | maintain | Buy →Speculative Buy | May 19, 2026 |
| Benchmark | maintain | Buy | May 19, 2025 |
| Benchmark | maintain | Buy | Nov 15, 2024 |
| Benchmark | maintain | Buy | Aug 16, 2024 |
| Benchmark | maintain | Buy | Aug 31, 2023 |
| Benchmark | maintain | Buy | Jul 5, 2023 |
| Benchmark | maintain | Buy | May 15, 2023 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.22| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.05 | $-0.10 | $12.0M | $9.5M |
| May 14, 2026 | $-0.41 | $-0.18 | $10.1M | $10.3M |
| Mar 19, 2026 | $0.50 | $0.20 | $17.1M | $16.1M |
| Nov 12, 2025 | $-0.59 | $-0.60 | $7.0M | $7.0M |
| Aug 13, 2025 | $-0.57 | $-0.45 | $9.0M | $8.3M |
| May 15, 2025 | $-0.47 | $-0.21 | $8.6M | $10.6M |
| Mar 21, 2025 | $-0.19 | $0.02 | $12.6M | $14.6M |
| Nov 13, 2024 | $-0.98 | $-0.83 | $9.0M | $10.0M |
News
WOBURN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S.-based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy, today announced that it will report financial results for the third quarter ended September 30, 2026 before the market opens on Friday, November 13, 2026.
Submission seeks to extend the Ameluz ® label beyond the face and scalp to treatment fields of up to approximately 240 cm² on the rest of the body, with an adjusted illumination protocol
Astrazeneca (NYSE: AZN - Get Free Report) and Biofrontera (NASDAQ: BFRI - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Institutional and Insider Ownership 20.4% of Astrazeneca shares are owned
Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera's photodynamic therapy platform
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.
WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026.